Corbus Pharmaceuticals Holdings, Inc.
CRBP
$6.37
$0.243.92%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 15.64M | 8.79M | 10.81M | 6.87M | 5.76M |
| Gross Profit | -15.64M | -8.79M | -10.81M | -6.87M | -5.76M |
| SG&A Expenses | 4.13M | 3.82M | 4.70M | 4.12M | 3.86M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.78M | 12.61M | 15.51M | 10.99M | 9.62M |
| Operating Income | -19.78M | -12.61M | -15.51M | -10.99M | -9.62M |
| Income Before Tax | -16.98M | -9.53M | -13.78M | -10.00M | -6.90M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -16.98M | -9.53M | -13.78M | -10.00M | -6.90M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.98M | -9.53M | -13.78M | -10.00M | -6.90M |
| EBIT | -19.78M | -12.61M | -15.51M | -10.99M | -9.62M |
| EBITDA | -19.69M | -12.47M | -15.35M | -10.84M | -9.47M |
| EPS Basic | -1.39 | -0.78 | -1.15 | -0.90 | -0.83 |
| Normalized Basic EPS | -0.87 | -0.49 | -0.72 | -0.57 | -0.52 |
| EPS Diluted | -1.39 | -0.78 | -1.15 | -0.90 | -0.83 |
| Normalized Diluted EPS | -0.87 | -0.49 | -0.72 | -0.57 | -0.52 |
| Average Basic Shares Outstanding | 12.20M | 12.18M | 12.01M | 11.05M | 8.31M |
| Average Diluted Shares Outstanding | 12.20M | 12.18M | 12.01M | 11.05M | 8.31M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |